urse-facilitated adherence therapy for haemophilia

Not Applicable

Completed

• Conditions: Haemophilia A or B; Haematological Disorders

• Registration Number: ISRCTN63283043
• Lead Sponsor: Canterbury Christ Church University (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-01
• Study Completion: 2015-09-01
• Last Update Posted: 26 October 2020

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 158

Inclusion Criteria

1. Patients with Haemophilia A or B being treated at one of the 10 haemophilia comprehensive care centres included in the trial
2. Aged 12 years or over who have been self-infusing clotting factor for a minimum of 6 months
3. Able to provide informed consent (or able to consent with parental/guardian agreement and signature)
4. With identified nonadherence issues (as determined by a score of =57 on the VERITASpro assessment measure)
5. English speaking and literate to a degree necessary to understand the PIS and the VERITASpro assessment measure and to complete the AnTHem workbook

Exclusion Criteria

1. Patients that do not meet the abovementioned criteria
2. Patients identified as having nontransient inhibitors to factor VIII or IX
3. Patients who during the period of the research develop nontransient inhibitors to factor VIII or IX

Study & Design

• Study Type: Interventional
• Study Design: Not specified